Literature DB >> 29040656

Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation.

Oscar O Agoro1, Sarah W Kibira1, Jenny V Freeman2, Hamish S F Fraser2.   

Abstract

Objective: Electronic pharmacovigilance reporting systems are being implemented in many developing countries in an effort to improve reporting rates. This study sought to establish the factors that acted as barriers to the success of an electronic pharmacovigilance reporting system in Kenya 3 years after its implementation. Materials and
Methods: Factors that could act as barriers to using electronic reporting systems were identified in a review of literature and then used to develop a survey questionnaire that was administered to pharmacists working in government hospitals in 6 counties in Kenya.
Results: The survey was completed by 103 out of the 115 targeted pharmacists (89.5%) and included free-text comments. The key factors identified as barriers were: unavailable, unreliable, or expensive Internet access; challenges associated with a hybrid system of paper and electronic reporting tools; and system usability issues. Coordination challenges at the national pharmacovigilance center and changes in the structure of health management in the country also had an impact on the success of the electronic reporting system. Discussion: Different personal, organizational, infrastructural, and reporting system factors affect the success of electronic reporting systems in different ways, depending on the context. Context-specific formative evaluations are useful in establishing the performance of electronic reporting systems to identify problems and ensure that they achieve the desired objectives.
Conclusion: While several factors hindered the optimal use of the electronic pharmacovigilance reporting system in Kenya, all were considered modifiable. Effort should be directed toward tackling the identified issues in order to facilitate use and improve pharmacovigilance reporting rates.

Mesh:

Year:  2018        PMID: 29040656      PMCID: PMC6664850          DOI: 10.1093/jamia/ocx102

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  63 in total

1.  Identifying barriers to the adoption of new technology in rural hospitals: a case report.

Authors:  Paula Garrett; C Andrew Brown; Susan Hart-Hester; Elgenaid Hamadain; Corey Dixon; William Pierce; William J Rudman
Journal:  Perspect Health Inf Manag       Date:  2006-10-25

2.  Pharmacovigilance in developing countries.

Authors:  Munir Pirmohamed; Kwame N Atuah; Alex N O Dodoo; Peter Winstanley
Journal:  BMJ       Date:  2007-09-08

3.  Pharmacovigilance knowledge in family paediatricians. A survey study in Italy.

Authors:  Paolo Pellegrino; Carla Carnovale; Dario Cattaneo; Valentina Perrone; Stefania Antoniazzi; Marco Pozzi; Ettore Napoleone; Maria Rosaria Filograna; Emilio Clementi; Sonia Radice
Journal:  Health Policy       Date:  2013-08-27       Impact factor: 2.980

Review 4.  Pharmacovigilance, risks and adverse effects of self-medication.

Authors:  Jean-Louis Montastruc; Emmanuelle Bondon-Guitton; Delphine Abadie; Isabelle Lacroix; Aurélia Berreni; Grégory Pugnet; Geneviève Durrieu; Laurent Sailler; Jean-Paul Giroud; Christine Damase-Michel; François Montastruc
Journal:  Therapie       Date:  2016-02-06       Impact factor: 2.070

5.  Magnetic resonance imaging research in sub-Saharan Africa: challenges and satellite-based networking implementation.

Authors:  Matthew T Latourette; James E Siebert; Robert J Barto; Kenneth L Marable; Anthony Muyepa; Colleen A Hammond; Michael J Potchen; Samuel D Kampondeni; Terrie E Taylor
Journal:  J Digit Imaging       Date:  2011-08       Impact factor: 4.056

6.  Optimizing Patient Surgical Management Using WhatsApp Application in the Italian Healthcare System.

Authors:  Bruno Nardo; Marco Cannistrà; Vincenzo Diaco; Agostino Naso; Matteo Novello; Alessandra Zullo; Michele Ruggiero; Raffaele Grande; Rosario Sacco
Journal:  Telemed J E Health       Date:  2016-03-30       Impact factor: 3.536

7.  A pharmacovigilance study in medicine department of tertiary care hospital in chhattisgarh (jagdalpur), India.

Authors:  H Singh; N Dulhani; Bn Kumar; P Singh; P Tewari; K Nayak
Journal:  J Young Pharm       Date:  2010-01

8.  Substandard and counterfeit medicines: a systematic review of the literature.

Authors:  Tariq Almuzaini; Imti Choonara; Helen Sammons
Journal:  BMJ Open       Date:  2013-08-17       Impact factor: 2.692

9.  Pharmacovigilance on sexual enhancing herbal supplements.

Authors:  Akshaya Srikanth Bhagavathula; Asim Ahmed Elnour; Abdulla Shehab
Journal:  Saudi Pharm J       Date:  2015-02-07       Impact factor: 4.330

10.  Texting-Based Reporting of Adverse Drug Reactions to Ensure Patient Safety: A Feasibility Study.

Authors:  Godofreda Vergeire-Dalmacion; Nina T Castillo-Carandang; Noel R Juban; Maria Lourdes Amarillo; Maria Pamela Tagle; Emmanuel S Baja
Journal:  JMIR Public Health Surveill       Date:  2015-11-19
View more
  4 in total

Review 1.  Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review.

Authors:  Halimat Adedeji-Adenola; Manimbulu Nlooto
Journal:  Int J Clin Pharm       Date:  2020-09-09

2.  The development of a pharmacovigilance system in Bahrain.

Authors:  Zainab Abdulrasool
Journal:  Saudi Pharm J       Date:  2022-03-15       Impact factor: 4.562

3.  Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.

Authors:  Jens-Ulrich Stegmann; Viviane Jusot; Olga Menang; Gregory Gardiner; Sabino Vesce; Stephanie Volpe; Anderson Ndalama; Felix Adou; Opokua Ofori-Anyinam; Olakunle Oladehin; Yolanda Guerra Mendoza
Journal:  BMC Public Health       Date:  2022-08-17       Impact factor: 4.135

4.  Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era.

Authors:  Renato Ferreira-da-Silva; Inês Ribeiro-Vaz; Manuela Morato; Jorge Junqueira Polónia
Journal:  Int J Clin Pharm       Date:  2021-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.